Management of aspirin intolerance in patients undergoing percutaneous coronary intervention: the role of mono-antiplatelet therapy. A retrospective, multicenter, study.
CONCLUSIONS: Our study evaluating patients with ACS or stable CAD undergoing PCI and treated with mono anti-platelet therapy with P2Y12 inhibitors due to aspirin intolerance shows a 25% incidence of POCE at one year. Further studies with adequate sample size are required to evaluate the efficacy and safety of mono anti-platelet therapy in this clinical scenario.
PMID: 30895761 [PubMed - as supplied by publisher]
Source: Minerva Cardioangiologica - Category: Cardiology Tags: Minerva Cardioangiol Source Type: research
More News: Allergy | Allergy & Immunology | Angioplasty | Aspirin | Cardiology | Clopidogrel | Coronary Angioplasty | Heart | Percutaneous Coronary Intervention | Plavix | Study | Women